Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents

Nakia Gray Scott, Jane Ripperger-Suhler, M. Hasan Rajab, Dean Kjar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: The aims of this study were to determine if relationships exist between the efficacy of atomoxetine for treatment of attention-deficit/ hyperactivity disorder (ADHD) and demographic characteristics, specific co-morbid diagnoses, subtype of ADHD, and/or additional use of a stimulant medication. Method: A retrospective chart review was performed using data from an institutional electronic medical record system. Children aged 5-17 years who were diagnosed with ADHD and prescribed atomoxetine were included; 432 study subjects were categorized as treatment success (TS), treatment failure (TF), or undetermined. Co-morbid diagnoses, demographic factors, subtype of ADHD, and additional use of stimulant medications were examined for association with TS. Results: A total of 88 children were categorized as TS, 197 as TF, and 147 as undetermined. More subjects in the TS group were receiving stimulant medication in addition to the atomoxetine than in the TF group (p? =? 0.0319; 95% Wald confidence interval [CI], 1.064-3.972). There was no significant difference between groups for any demographic characteristic, the presence of any co-morbid diagnosis, or type of ADHD. In particular, the presence of anxiety or depression was not associated with a response to atomoxetine. Conclusion: Children who were prescribed a stimulant medication in addition to atomoxetine had better outcomes in treating ADHD than those receiving only atomoxetine.

Original languageEnglish (US)
Pages (from-to)197-203
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Volume20
Issue number3
DOIs
StatePublished - Jun 1 2010

Fingerprint

Attention Deficit Disorder with Hyperactivity
Treatment Failure
Demography
Electronic Health Records
Therapeutics
Atomoxetine Hydrochloride
Anxiety
Confidence Intervals
Depression

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. / Scott, Nakia Gray; Ripperger-Suhler, Jane; Rajab, M. Hasan; Kjar, Dean.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 20, No. 3, 01.06.2010, p. 197-203.

Research output: Contribution to journalArticle

Scott, Nakia Gray ; Ripperger-Suhler, Jane ; Rajab, M. Hasan ; Kjar, Dean. / Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents. In: Journal of Child and Adolescent Psychopharmacology. 2010 ; Vol. 20, No. 3. pp. 197-203.
@article{69eb1cd8e8bf42668dcc8f9d0fd0bd88,
title = "Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents",
abstract = "Objectives: The aims of this study were to determine if relationships exist between the efficacy of atomoxetine for treatment of attention-deficit/ hyperactivity disorder (ADHD) and demographic characteristics, specific co-morbid diagnoses, subtype of ADHD, and/or additional use of a stimulant medication. Method: A retrospective chart review was performed using data from an institutional electronic medical record system. Children aged 5-17 years who were diagnosed with ADHD and prescribed atomoxetine were included; 432 study subjects were categorized as treatment success (TS), treatment failure (TF), or undetermined. Co-morbid diagnoses, demographic factors, subtype of ADHD, and additional use of stimulant medications were examined for association with TS. Results: A total of 88 children were categorized as TS, 197 as TF, and 147 as undetermined. More subjects in the TS group were receiving stimulant medication in addition to the atomoxetine than in the TF group (p? =? 0.0319; 95{\%} Wald confidence interval [CI], 1.064-3.972). There was no significant difference between groups for any demographic characteristic, the presence of any co-morbid diagnosis, or type of ADHD. In particular, the presence of anxiety or depression was not associated with a response to atomoxetine. Conclusion: Children who were prescribed a stimulant medication in addition to atomoxetine had better outcomes in treating ADHD than those receiving only atomoxetine.",
author = "Scott, {Nakia Gray} and Jane Ripperger-Suhler and Rajab, {M. Hasan} and Dean Kjar",
year = "2010",
month = "6",
day = "1",
doi = "10.1089/cap.2009.0104",
language = "English (US)",
volume = "20",
pages = "197--203",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents

AU - Scott, Nakia Gray

AU - Ripperger-Suhler, Jane

AU - Rajab, M. Hasan

AU - Kjar, Dean

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Objectives: The aims of this study were to determine if relationships exist between the efficacy of atomoxetine for treatment of attention-deficit/ hyperactivity disorder (ADHD) and demographic characteristics, specific co-morbid diagnoses, subtype of ADHD, and/or additional use of a stimulant medication. Method: A retrospective chart review was performed using data from an institutional electronic medical record system. Children aged 5-17 years who were diagnosed with ADHD and prescribed atomoxetine were included; 432 study subjects were categorized as treatment success (TS), treatment failure (TF), or undetermined. Co-morbid diagnoses, demographic factors, subtype of ADHD, and additional use of stimulant medications were examined for association with TS. Results: A total of 88 children were categorized as TS, 197 as TF, and 147 as undetermined. More subjects in the TS group were receiving stimulant medication in addition to the atomoxetine than in the TF group (p? =? 0.0319; 95% Wald confidence interval [CI], 1.064-3.972). There was no significant difference between groups for any demographic characteristic, the presence of any co-morbid diagnosis, or type of ADHD. In particular, the presence of anxiety or depression was not associated with a response to atomoxetine. Conclusion: Children who were prescribed a stimulant medication in addition to atomoxetine had better outcomes in treating ADHD than those receiving only atomoxetine.

AB - Objectives: The aims of this study were to determine if relationships exist between the efficacy of atomoxetine for treatment of attention-deficit/ hyperactivity disorder (ADHD) and demographic characteristics, specific co-morbid diagnoses, subtype of ADHD, and/or additional use of a stimulant medication. Method: A retrospective chart review was performed using data from an institutional electronic medical record system. Children aged 5-17 years who were diagnosed with ADHD and prescribed atomoxetine were included; 432 study subjects were categorized as treatment success (TS), treatment failure (TF), or undetermined. Co-morbid diagnoses, demographic factors, subtype of ADHD, and additional use of stimulant medications were examined for association with TS. Results: A total of 88 children were categorized as TS, 197 as TF, and 147 as undetermined. More subjects in the TS group were receiving stimulant medication in addition to the atomoxetine than in the TF group (p? =? 0.0319; 95% Wald confidence interval [CI], 1.064-3.972). There was no significant difference between groups for any demographic characteristic, the presence of any co-morbid diagnosis, or type of ADHD. In particular, the presence of anxiety or depression was not associated with a response to atomoxetine. Conclusion: Children who were prescribed a stimulant medication in addition to atomoxetine had better outcomes in treating ADHD than those receiving only atomoxetine.

UR - http://www.scopus.com/inward/record.url?scp=77954940454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954940454&partnerID=8YFLogxK

U2 - 10.1089/cap.2009.0104

DO - 10.1089/cap.2009.0104

M3 - Article

C2 - 20578932

AN - SCOPUS:77954940454

VL - 20

SP - 197

EP - 203

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 3

ER -